Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q4 FY21 results · Jan–Mar 2021
Wockhardt reported revenue from operations of ₹631.96 crore (down 8.0% from Q4 FY20) and net loss of ₹106.84 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 631.96 | 686.93 | −8.0% | 764.02 | −17.3% |
| Other income | 7.54 | 13.73 | −45.1% | 100.54 | −92.5% |
| Total income | 639.50 | 700.66 | −8.7% | 864.56 | −26.0% |
| Profit before tax | (178.18) | (95.13) | Loss widened | 31.19 | Turned loss |
| Net profit for the period | (106.84) | 68.51 | Turned loss | 32.40 | Turned loss |
| Attributable to shareholders of the company | (92.79) | 48.29 | Turned loss | 15.24 | Turned loss |
| EPS, basic (₹) | (8.38) | 4.36 | Turned loss | 1.38 | Turned loss |
| Net margin (%) | -16.9 | 10.0 | 4.2 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 261.75 | 162.21 | +61.4% | 252.97 | +3.5% |
| Other income | 6.31 | 12.62 | −50.0% | 9.72 | −35.1% |
| Total income | 268.06 | 174.83 | +53.3% | 262.69 | +2.0% |
| Profit before tax | (113.24) | (150.24) | Loss narrowed | (90.26) | Loss widened |
| Net profit for the period | (47.05) | (78.48) | Loss narrowed | (68.67) | Loss narrowed |
| EPS, basic (₹) | (4.25) | (7.08) | Loss narrowed | (6.20) | Loss narrowed |
| Net margin (%) | -18.0 | -48.4 | -27.1 |
Consolidated
- Filed with BSE
- 28 May 2021, 14:35 IST
- Board meeting
- 27 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 May 2021, 14:35 IST
- Board meeting
- 27 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE